European Business
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
European Business
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
European Business
No Result
View All Result
Home < INDUSTRIES Health

Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentations at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress

by Alex Weber
May 9, 2023
A A
Share on LinkedinShare on Twitter

NEW HAVEN, Conn., and NEW YORK — Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced they will present updated data related to vepdegestrant (ARV-471) at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress.  Vepdegestrant is a novel investigational PROTAC® estrogen receptor (ER) protein degrader that is being jointly developed by Arvinas and Pfizer for the treatment of patients with early and locally advanced or metastatic ER positive/human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer. Four posters will be presented during the poster session at the annual congress, which will be held from May 11-13, 2023, in Berlin, Germany. 

Poster session details are as follows:
Date: Friday, May 12, 2023
Time: 12:15 – 1:00 p.m. CET/ 6:15 – 7:00 a.m. ET

•    VERITAC update: phase 2 study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer (Poster 205P)

•    VERITAC-2: a global, randomized phase 3 study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, vs fulvestrant in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer (Poster 257TiP)

•    TACTIVE-N: open-label, randomized, noncomparative neoadjuvant phase 2 study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, or anastrozole in postmenopausal women with ER+/human epidermal growth factor receptor 2 (HER2)- localized breast cancer (Poster 154TiP)

•    TACTIVE-E: phase 1b study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in combination with everolimus in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer (Poster 256TiP)

Tags: < New Launches

Related Industries

Health

BD Opens New €4 Million R&D Centre in Dublin, Will Invest Additional €30 Million in Enniscorthy Manufacturing Plant

June 3, 2023
Health

RECKITT ANNOUNCES PATRICK SLY AS PRESIDENT OF HEALTH AND SUSAN SHOLTIS AS PRESIDENT OF NUTRITION

June 2, 2023
Health

Bayer to acquire exclusive license from Cedilla Therapeutics on selective inhibitors in pre-clinical precision oncology

June 2, 2023
Health

Merck Increases Global Commitment to Biosafety Testing With € 35 Million Investment in Scotland

June 1, 2023
Health

Philips launches AI-powered CT system to accelerate routine radiology and high-volume screening programs

May 18, 2023
Health

Siemens Healthineers opens state-of-the-art education and development center in Erlangen, Germany

May 18, 2023

Barclays announces new leadership for Global Equities

May 24, 2023

...

CVC wins two awards at the GlobalCapital European Securitization Awards 2023

May 17, 2023

...

Barclays appoints Foruhar Madjlessi as Co-Head of Equity Capital Markets for EMEA

May 12, 2023

...

Nestlé announces François-Xavier Roger stepping down, Anna Manz named as CFO

June 1, 2023

...

OPPO Announces Kaká as Global Brand Ambassador for its UEFA Champions League Partnership

May 26, 2023

...

Visa Plans New Global Technology and Product Hub in Poland to Support 24/7 Development Model for Innovation

May 24, 2023

...

Stellantis and Galloo to Form Joint Venture for End-of-Life Vehicle Recycling

June 6, 2023

...

Lenovo and Leibniz Supercomputing Centre Build First European HPC System Prototype Within Innovation Partnership

May 18, 2023

...

New Lenovo Supercomputer for Potsdam Institute for Climate Impact Research

May 18, 2023

...

Siemens Mobility acquires Optrail to expand its Train Planning System functionalities

June 2, 2023

...

Asia Pacific Business Asia Pacific Business Asia Pacific Business

EUROPEAN BUSINESS is a premier source of corporate news, business information and insights across broad spectrum of industries in Europe and worldwide.  We are one of the members of the Business World Network.

RESOURCES

  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

CONTACT US

EDITORIAL:     editor # european-biz.com

PARTNERSHIP:     partnership # european-biz.com

HUMAN RESOURCE:     hr # european-biz.com

* (replace # with @)

  • Official Site

Copyright © EUROPEAN-BIZ.COM All rights reserved.

No Result
View All Result
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

Copyright © EUROPEAN-BIZ.COM All rights reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist